Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
GPT Healthcare Ltd (GPTHEALTH)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544131 NSE: GPTHEALTH Hospital & Healthcare Services | Small Cap | GPT Healthcare Share Price
₹165.85 5.85 (3.66%)
As on 27-Jul'26 16:59
GPT Healthcare Ltd (GPTHEALTH)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544131 NSE: GPTHEALTH Hospital & Healthcare Services | Small Cap | GPT Healthcare Share Price
₹165.85 5.85 (3.66%)
As on 27-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹1,361 Cr.
Current Price
₹165.9
52-Week Low / High
₹114 / 185
TTM EPS
₹5.2
TTM Sales
₹473 Cr.
Book Value per Share
₹32.8
P/E Ratio
32.23
Higher than its 5-year historical median
Industry PE
97.6
Price to Book (P/B)
5.05
Higher than its 5-year historical median
Price to Sales (P/S)
2.88
Higher than its 5-year historical median
EV/EBITDA
15.23
Higher than its 5-year historical median
Dividend Yield
1.51%
Profitability Efficiency
Return on Equity (ROE)
16.32%
Outperforms industry median
Return on Capital Employed (ROCE)
23.06%
Outperforms industry median
Return on Assets (ROA)
9.50%
Operating Profit Margin
18.1%
Net Profit Margin
8.93%
Gross Profit Margin
17.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
16.08%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
1%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-15.42%
Asset Quality
Promoter Holding
65.57%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹187 Cr.
Equity
₹82.1 Cr.
Face Value
₹10
All Time Low / High
₹114.00 / 219.70
Check Before You Invest
Quality
Very GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is GPT Healthcare Ltd a good quality company?
GPT Healthcare Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does GPT Healthcare Ltd performance compare with that of its Peers?
Revenue growth of GPT Healthcare Ltd vs industry peers?
GPT Healthcare Ltd revenue CAGR is 14.25%, compared to the industry median CAGR of 2.98%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of GPT Healthcare Ltd?
Promoters hold 65.57% of the GPT Healthcare Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of GPT Healthcare Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 1.7% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
GPT Healthcare Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 11.8% | 16.1% | 13% | 17.1% | 25.6% | 26.9% | 32.6% | 29.6% | 23.1% | - |
| Value Creation Index ⓘ | NA | -0.2 | 0.2 | -0.1 | 0.2 | 0.8 | 0.9 | 1.3 | 1.1 | 0.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 146 | 172 | 212 | 243 | 337 | 361 | 400 | 407 | 473 | 473 |
| Sales YoY Gr. | - | NA | 17.5% | 23.3% | 14.6% | 39% | 7% | 10.8% | 1.7% | 16.1% | - |
| Adj EPS ⓘ | 0 | 1.4 | 2.8 | 2.1 | 3.8 | 5.2 | 4.8 | 5.8 | 6.1 | 5.2 | 5.2 |
| YoY Gr. | - | NA | 98.6% | -27% | 85.9% | 35.8% | -6.9% | 20.5% | 3.8% | -13.4% | - |
| BVPS (₹) ⓘ | 0 | 18.7 | 21.5 | 16.1 | 17.5 | 19.8 | 20.7 | 26.6 | 30.2 | 32.8 | 32.8 |
| Adj Net Profit ⓘ | 0 | 7.7 | 15.2 | 11.1 | 20.6 | 41.5 | 38.7 | 47.8 | 49.7 | 43 | 42 |
| Cash Flow from Ops. ⓘ | 0 | 22.3 | 31.7 | 41.5 | 43 | 66 | 66.4 | 68.8 | 67.4 | 81.2 | - |
| Debt/CF from Ops. ⓘ | 0 | 3.5 | 2.8 | 2.7 | 2.9 | 1.5 | 1 | 0.2 | 0.2 | 0.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 14.3% | 9.4% | 16.1% | ||||
| Adj EPS ⓘ | NA | 6.5% | 2.7% | -13.4% | ||||
| BVPSⓘ | NA | 13.5% | 16.6% | 8.7% | ||||
| Share Price | - | - | - | 4% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 7.6 | 14 | 9.2 | 15.8 | 28.4 | 23.9 | 24.9 | 21.3 | 16.6 | 15.7 |
| Op. Profit Mgn % ⓘ | 0 | 17.7 | 21.2 | 17 | 20.2 | 21.9 | 20.6 | 22 | 20.5 | 18.1 | 17.8 |
| Net Profit Mgn % ⓘ | 0 | 5.2 | 8.8 | 5.2 | 8.5 | 12.3 | 10.7 | 12 | 12.2 | 9.1 | 8.9 |
| Debt to Equity ⓘ | 0 | 0.8 | 0.8 | 0.9 | 0.9 | 0.6 | 0.4 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 0 | 0 | 105 | 114 | 121 | 89 | 93 | 101 | 96 | 73 | 32 |
| Cash Conv. Cycle ⓘ | 0 | 0 | -30 | -25 | -21 | -14 | -14 | -13 | -14 | -14 | 2 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 146 | 172 | 212 | 243 | 337 | 361 | 400 | 407 | 473 |
| Operating Expenses ⓘ + | 120 | 136 | 176 | 194 | 264 | 287 | 312 | 324 | 388 |
| Operating Profit ⓘ | 26 | 36 | 36 | 49 | 74 | 74 | 88 | 83 | 84 |
| Operating Profit Margin (%) | 17.6% | 21.0% | 16.9% | 20.2% | 21.9% | 20.6% | 21.9% | 20.5% | 17.8% |
| Other Income ⓘ + | 4 | 3 | 4 | 6 | 5 | 6 | 5 | 8 | 6 |
| Interest ⓘ | 10 | 10 | 14 | 14 | 11 | 9 | 7 | 3 | 8 |
| Depreciation ⓘ | 8 | 9 | 11 | 12 | 14 | 15 | 18 | 19 | 27 |
| Profit Before Tax ⓘ | 11 | 20 | 15 | 29 | 54 | 56 | 68 | 69 | 55 |
| Tax ⓘ | 3 | 5 | 4 | 8 | 12 | 17 | 20 | 19 | 13 |
| Profit After Tax | 8 | 15 | 11 | 21 | 42 | 39 | 48 | 50 | 42 |
| PAT Margin (%) | 5.2% | 8.7% | 5.2% | 8.7% | 12.4% | 10.8% | 11.9% | 12.3% | 8.9% |
| Adjusted EPS (₹) | 1.4 | 2.8 | 2.0 | 3.1 | 5.2 | 4.9 | 5.8 | 6.1 | 5.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 24.60% | 63.70% | 134.30% | 81.90% | 60.10% | 41.10% | 48.60% |
Valuation of GPT Healthcare - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 101 | 116 | 127 | 134 | 158 | 165 | 218 | 248 | 269 | ||
| Debt + | 60 | 79 | 103 | 104 | 76 | 42 | 6 | 8 | 7 | ||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Trade Payables | 23 | 23 | 33 | 26 | 29 | 33 | 37 | 35 | 42 | ||
| Others Liabilities ⓘ | 32 | 29 | 42 | 47 | 57 | 115 | 125 | 118 | 162 | ||
| Total Liabilities ⓘ | 216 | 247 | 305 | 311 | 320 | 356 | 387 | 408 | 481 | ||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 153 | 156 | 226 | 220 | 220 | 228 | 224 | 228 | 342 | ||
| CWIP ⓘ | 20 | 33 | 2 | 0 | 1 | 3 | 6 | 46 | 1 | ||
| Investments ⓘ | 0 | 0 | 1 | 1 | 10 | 13 | 30 | 32 | 43 | ||
| Inventories | 4 | 5 | 6 | 6 | 7 | 9 | 8 | 9 | 11 | ||
| Trade Receivables | 12 | 11 | 17 | 17 | 13 | 21 | 24 | 20 | 20 | ||
| Cash Equivalents | 0 | 1 | 1 | 5 | 9 | 9 | 9 | 4 | 4 | ||
| Others Assets ⓘ | 26 | 41 | 52 | 61 | 59 | 74 | 85 | 69 | 60 | ||
| Total Assets ⓘ | 216 | 247 | 305 | 311 | 320 | 356 | 387 | 408 | 481 | ||
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 22 | 32 | 41 | 43 | 66 | 66 | 69 | 67 | 81 |
| Cash Flow From Investing Activity ⓘ + | -6 | -31 | -54 | -16 | -5 | 5 | -25 | -33 | -47 |
| Cash Flow From Financing Activity ⓘ + | -16 | 0 | 12 | -22 | -57 | -73 | -49 | -35 | -31 |
| Net Cash Flow ⓘ | -0 | 1 | -1 | 4 | 3 | -2 | -5 | -0 | 2 |
Financial Ratio
| PARTICULARS | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 7.52 | 13.87 | 10.81 | 23.34 | 33.05 | 24.11 | 24.89 | 21.41 | 16.32 | |
| ROCE (%) | 11.78 | 16.07 | 13.04 | 17.14 | 25.56 | 26.93 | 32.61 | 29.6 | 23.06 | |
| Asset Turnover Ratio | 0.68 | 0.74 | 0.77 | 0.79 | 1.07 | 1.07 | 1.08 | 1.02 | 1.06 | |
| PAT to CFO Conversion(x) | 2.75 | 2.13 | 3.73 | 2.05 | 1.57 | 1.69 | 1.44 | 1.34 | 1.93 | |
| Working Capital Days | ||||||||||
| Receivable Days | 30.50 | 24.70 | 24.40 | 26 | 16.60 | 17.20 | 20.50 | 19.70 | 15.40 | |
| Inventory Days | 9.90 | 9.20 | 9.50 | 9.60 | 7.40 | 8.20 | 7.80 | 7.60 | 7.50 | |
| Payable Days | 317.70 | 276.40 | 266.40 | 187.60 | 114.50 | 149.90 | 155.70 | 167.10 | 155.80 | |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
GPT Healthcare Ltd FAQs
The current trading price of GPT Healthcare on 27-Jul-2026 16:59 is ₹165.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Jul-2026 the market cap of GPT Healthcare stood at ₹1,360.9 Cr
The latest P/E ratio of GPT Healthcare as of 26-Jul-2026 is 32.23.
The latest P/B ratio of GPT Healthcare as of 26-Jul-2026 is 5.05.
The 52-week high of GPT Healthcare is ₹184.8 and the 52-week low is ₹114.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of GPT Healthcare is ₹473 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that GPT Healthcare Ltd is a good quality company.
The key valuation ratios of GPT Healthcare Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of GPT Healthcare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About GPT Healthcare Ltd
GPT Healthcare Limited was originally incorporated as ‘Jibansatya Printing House Private Limited’, a private limited company under the Companies Act, 1956 on August 17, 1989 at Kolkata, West Bengal. The name of the Company was subsequently changed to ‘GPT Healthcare Private Limited’ so that the name of the Company is in consonance with the main objects of the Memorandum of Association in relation to the proposed business activities to be carried out by the Company. A fresh certificate of incorporation was issued by the RoC on March 31, 2005. Thereafter, pursuant to a special resolution passed by its shareholders on September 3, 2021, the Company was converted to a public limited company and its name was changed to ‘GPT Healthcare Limited’. A fresh certificate of incorporation consequent to change of name was issued by the RoC on September 15, 2021.
GPT Healthcare is one of the key regional corporate healthcare companies in Eastern India in terms of number of beds and hospitals as of Fiscal Year 2023. The Principal activities of the company include operation of multidisciplinary private hospitals and pharmacies. The company operates a chain of mid-sized full service hospitals under the brand and provides integrated healthcare services, with a focus on secondary and tertiary care. As of September 30, 2023, the company operates four multispecialty hospitals in Dum Dum, Salt Lake and Howrah in West Bengal and Agartala in Tripura. It offers a comprehensive range of healthcare services across many specialties and super specialties, including internal medicine and diabetology, nephrology (including renal transplants), laparoscopic and general surgery, gynaecology and obstetrics, critical care, gastroenterology, orthopaedics and joint replacements, interventional cardiology, neurology, neurosurgery, paediatrics, and neonatology. Each of its hospitals also provides integrated diagnostic services and pharmacies that cater to its patients.
The company strategically focuses on the relatively under-penetrated healthcare market in Eastern India where it has presence in three cities which has provided it an understanding of regional nuances, patient culture and the mindset of medical professionals and where there is under-penetration of quality and affordable healthcare services.
Business area of the company
The company is engaged in the business of providing healthcare services. The company operates a chain of mid-sized full service hospitals under the brand and provides integrated healthcare services, with a focus on secondary and tertiary care.
Awards, accreditations or recognitions
- 2016: Surgical Review Corporation accredited its hospital in Salt Lake, West Bengal as Centre for Excellence-Metabolic / Bariatric Surgery.
- 2020: National Accreditation Board for Testing and Calibration Laboratories accredited its Dum Dum Hospital with ISO 15189:2012 for ‘Medical Laboratories - Requirements for Quality and Competence’.
- 2020: ILS Hospitals and the Company were awarded the ‘Sanmarg Business Award 2020’ in the category of ‘Medium Scale Services & Trade’.
- 2020: National Board of Exams provided provisional accreditation to the department of Minimal Access Surgery at its hospital in Salt Lake City, West Bengal to provide post graduate training facilities for FNB - Minimal Access Surgery Programme.
- 2021: National Accreditation Board for Hospitals and Healthcare Providers provided a certificate of accreditation to its Dum Dum Hospital for complying with NABH Accreditation Standards for Hospitals.
- 2021: National Accreditation Board for Hospitals and Healthcare Providers provided a certificate of accreditation to its Agartala Hospital for complying with NABH Accreditation Standards for Hospitals.
- 2021: Its Agartala Hospital was awarded the ‘AHPI Award 2021’ in ‘Excellence for Community Engagement’ from the Association of Healthcare Providers (India).
- 2021: ILS Hospitals was awarded the ‘Iconic Healthcare Summit & Awards 2021’ by Topgallant Media.
- 2022: Its Salt Lake Hospital was awarded and received a certificate of honour for ‘Excellence in Customer Care & Support’ at the ‘ABP Ananda Swashthya Samman 2022’.
- 2022: ILS Hospitals was awarded and received a certificate of honour for ‘Outstanding Hospital Chain at the ‘ABP Ananda Swasthya Samman 2022’.
- 2023 National Accreditation Board for Testing and Calibration Laboratories accredited its Agartala Hospital with ISO 15189:2012 for ‘Medical Laboratories - Requirements for Quality and Competence’.
History and milestones
- 1989: Incorporation of the Company.
- 2000: Company started the hospital business in Salt Lake, West Bengal.
- 2005: Tantia Medical Services Private Limited sold its nursing home business to the Company on a going concern basis.
- 2008: Company signed lease agreement for its multi-specialty Agartala Hospital.
- 2011: Commissioned its Agartala Hospital with a capacity of 205 beds with a Nursing School.
- 2013: Commissioned its Dum Dum Hospital.
- 2016: Its Dum Dum Hospital received permission to provide kidney transplantation service.
- 2019: Commissioned its Howrah Hospital.
- 2021: Initiated B.Sc Nursing Programme with an intake capacity of 45 students in its Agartala Hospital.
- 2021: Signed a lease agreement for a new hospital in Ranchi on September 17, 2021.
- 2023: Signed a memorandum of understanding for the construction and finishing of a hospital building at Raipur on January 16, 2023.
- 2023: Signed a cancer care department management agreement to set up and operate the cancer care department at its Agartala Hospital on September 1, 2023.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
